Cytori Therapeutics to Participate in Stem Cell Therapy Focus Session at the BIO CEO & Investor Conference

San Diego, CA, February 9, 2006 – Cytori Therapeutics, Inc., (NASDAQ: CYTX; Frankfurt: XMPA) announced today that Marc H. Hedrick, M.D., President of Cytori Therapeutics, will participate in a focus session entitled, "Cell Therapy: Getting Around the Embryonic Stem Cell Issue," on Wednesday, February 15, 2006 from 3:30 p.m. to 4:55 p.m. Eastern Standard Time, at the Biotechnology Industry Organization (BIO) CEO & Investor Conference, in New York City, NY.

The focus panel will examine how companies are translating technological breakthroughs in stem cell research into innovative treatments. The session will be moderated by Michael Werner, Esq., President at The Werner Group. The panelists in addition to Dr. Hedrick, are Reni Benjamin, Senior Biotechnology Analyst, Rodman & Renshaw, LLC; Mr. Bruce Cohen, President and CEO, Cellerant Therapeutics, Inc.; Dr. Thomas Okarma, President and CEO, Geron Corporation and Mr. James Stewart, Senior Vice President and CFO, Advanced Cell Technologies.

The focus session will be webcast live and may be accessed through the Company's website at http://ir.cytoritx.com/webcasts.cfm under the "News and Events" section of the Company's website.

About Cytori Therapeutics

Cytori Therapeutics, Inc., (NASDAQ: CYTX; Frankfurt: XMPA) is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution™ System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.

Tom Baker
Investors
Tel. 858-875-5258
tbaker@cytoritx.com

Amy Beltran, Ph.D.
Media (Porter Novelli Life Sciences)
Tel. 858-527-3489
abeltran@pnlifesciences.com